Stifel Nicolaus Lowers Aratana Therapeutics (PETX) Price Target to $7.00

Aratana Therapeutics (NASDAQ:PETX) had its price objective trimmed by Stifel Nicolaus from $8.00 to $7.00 in a research note published on Monday, Marketbeat Ratings reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on PETX. Zacks Investment Research downgraded Aratana Therapeutics from a hold rating to a sell rating in a report on Saturday, July 7th. ValuEngine upgraded Aratana Therapeutics from a sell rating to a hold rating in a report on Friday, June 15th. BidaskClub upgraded Aratana Therapeutics from a hold rating to a buy rating in a report on Thursday, May 10th. Finally, HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a buy rating in a report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $8.21.

Aratana Therapeutics opened at $5.07 on Monday, according to Marketbeat Ratings. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.02 and a quick ratio of 2.82. Aratana Therapeutics has a 12 month low of $3.67 and a 12 month high of $7.28.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $4.91 million during the quarter, compared to the consensus estimate of $4.72 million. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. research analysts predict that Aratana Therapeutics will post -0.48 EPS for the current year.

In other Aratana Therapeutics news, insider Peter Steven St sold 11,513 shares of the stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $4.33, for a total value of $49,851.29. Following the completion of the sale, the insider now directly owns 649,233 shares in the company, valued at $2,811,178.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $4.56, for a total value of $45,600.00. Following the completion of the sale, the chief operating officer now owns 99,967 shares of the company’s stock, valued at $455,849.52. The disclosure for this sale can be found here. 5.30% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Aratana Therapeutics by 25.7% in the fourth quarter. Wells Fargo & Company MN now owns 461,612 shares of the biopharmaceutical company’s stock worth $2,428,000 after acquiring an additional 94,247 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Aratana Therapeutics by 23.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock worth $398,000 after acquiring an additional 17,300 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Aratana Therapeutics by 0.5% in the first quarter. Franklin Resources Inc. now owns 5,969,371 shares of the biopharmaceutical company’s stock worth $26,325,000 after acquiring an additional 28,969 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Aratana Therapeutics by 30.5% in the first quarter. Dimensional Fund Advisors LP now owns 785,096 shares of the biopharmaceutical company’s stock worth $3,462,000 after acquiring an additional 183,294 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new position in shares of Aratana Therapeutics during the fourth quarter worth about $110,000. Institutional investors own 67.82% of the company’s stock.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Further Reading: Google Finance

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply